Leptin signalling, obesity and prostate cancer: Molecular and clinical perspective on the old dilemma

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35556-35563

  Alshaker, Heba ^a,b   Sacco, Keith ^c   Alfraidi, Albandri ^a   Muhammad, Aun ^a   Winkler, Mathias ^a   Pchejetski, Dmitri ^d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PETRA   (Jordan)

^c UNIVERSITY OF MALTA MEDICAL SCHOOL   (Malta)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Adipokine; BMI; Leptin; Mortality; Obesity; Progression; Prostate cancer; Therapy

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR; GLUCOSE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 2; LEPTIN; LEPTIN RECEPTOR; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE SHP 2; SPHINGOSINE KINASE 1; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VITRONECTIN RECEPTOR; JANUS KINASE;

ADIPOSE TISSUE; ARTICLE; BODY MASS; BROWN ADIPOSE TISSUE; CANADA; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CELL INVASION; CELL MIGRATION; CHOLESTEROL BLOOD LEVEL; DIETARY INTAKE; DISEASE ASSOCIATION; ENZYME ACTIVATION; ESTROGEN METABOLISM; EUROPEAN AMERICAN; GLEASON SCORE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LEPR GENE; LONG TERM EXPOSURE; METABOLIC SYNDROME X; MOLECULAR LIBRARY; NONHUMAN; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; THERMOGENESIS; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ANIMAL; CARCINOGENESIS; COMPLICATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; ANIMALS; CARCINOGENESIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JANUS KINASES; LEPTIN; MALE; OBESITY; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, LEPTIN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84946854574     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5574     Document Type: Article

References (64)

1. Kelly T, Yang W, Chen CS, Reynolds K and He J. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008; 32:1431-1437.
2. Calle EE and Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4:579-591.
3. Calle EE, Rodriguez C, Walker-Thurmond K and Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348:1625-1638.
4. Vucenik I and Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci. 2012; 1271:37-43.
5. Byers T and Sedjo RL. Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocr Relat Cancer. 2015; 22:R125-R134.
6. Renehan AG, Tyson M, Egger M, Heller RF and Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371:569-578.
7. Bassett JK, Severi G, Baglietto L, Macinnis RJ, Hoang HN, Hopper JL, English DR and Giles GG. Weight change and prostate cancer incidence and mortality. Int J Cancer. 2011; 31:27414.
8. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A and Leitzmann MF. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007; 109:675-684.
9. Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC and Giovannucci E. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev. 2005; 14:1262-1269.
10. Allott EH, Masko EM and Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013; 63:800-809.
11. De Nunzio C, Freedland SJ, Miano L, Finazzi Agro E, Banez L and Tubaro A. The uncertain relationship between obesity and prostate cancer: an Italian biopsy cohort analysis. Eur J Surg Oncol. 2011; 37:1025-1029.
12. De Nunzio C, Albisinni S, Freedland SJ, Miano L, Cindolo L, Finazzi Agro E, Autorino R, De Sio M, Schips L and Tubaro A. Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study. Urol Oncol. 2013; 31:997-1002.
13. Bhindi B, Locke J, Alibhai SM, Kulkarni GS, Margel DS, Hamilton RJ, Finelli A, Trachtenberg J, Zlotta AR, Toi A, Hersey KM, Evans A, van der Kwast TH and Fleshner NE. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort. Eur Urol. 2015; 67:64-70.
14. Conteduca V, Caffo O, Derosa L, Veccia A, Petracci E, Chiuri VE, Santoni M, Santini D, Fratino L, Maines F, Testoni S and De Giorgi U. Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. Prostate. 2015; 75:1329-38.
15. Su LJ, Arab L, Steck SE, Fontham ET, Schroeder JC, Bensen JT and Mohler JL. Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study. Cancer Epidemiol Biomarkers Prev. 2011; 20:844-853.
16. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ and Calle EE. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007; 16:63-69.
17. Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, Gronberg H and Stanford JL. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev. 2011; 20:1928-1936.
18. Chang S, Hursting SD, Contois JH, Strom SS, Yamamura Y, Babaian RJ, Troncoso P, Scardino PS, Wheeler TM, Amos CI and Spitz MR. Leptin and prostate cancer. Prostate. 2001; 46:62-67.
19. Drake I, Sonestedt E, Gullberg B, Ahlgren G, Bjartell A, Wallstrom P and Wirfalt E. Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmo Diet and Cancer cohort. Am J Clin Nutr. 2012; 96:1409-1418.
20. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC and Giovannucci EL. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr. 2004; 80:204-216.
21. De Pergola G and Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013; 2013:291546.
22. De Nunzio C, Presicce F, Lombardo R, Cancrini F, Petta S, Trucchi A, Gacci M, Cindolo L and Tubaro A. Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis. BJU Int. 2015. [Epub ahead of print].
23. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, deGregorio F, Elshimali YI, Heber D and Aronson WJ. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res. 2003; 9:2734-2743.
24. Hoon Kim J, Lee SY, Myung SC, Kim YS, Kim TH and Kim MK. Clinical significance of the leptin and leptin receptor expressions in prostate tissues. Asian J Androl. 2008; 10:923-928.
25. Stattin P, Kaaks R, Johansson R, Gislefoss R, Soderberg S, Alfthan H, Stenman UH, Jellum E and Olsson T. Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 2003; 12:474-475.
26. Mistry T, Digby JE, Desai KM and Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007; 52:46-53.
27. Freedland SJ and Aronson WJ. Obesity and prostate cancer. Urology. 2005; 65:433-439.
28. Price RS, Cavazos DA, De Angel RE, Hursting SD and deGraffenried LA. Obesity-related systemic factors promote an invasive phenotype in prostate cancer cells. Prostate Cancer Prostatic Dis. 2012; 15:135-143.
29. Alshaker H, Krell J, Frampton AE, Waxman J, Blyuss O, Zaikin A, Winkler M, Stebbing J, Yague E and Pchejetski D. Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway. Breast Cancer Res. 2014; 16:426.
30. Alshaker H, Wang Q, Frampton AE, Krell J, Waxman J, Winkler M, Stebbing J, Cooper C, Yague E and Pchejetski D. Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2015; 149:59-67.
31. Malavaud B, Pchejetski D, Mazerolles C, de Paiva GR, Calvet C, Doumerc N, Pitson S, Rischmann P and Cuvillier O. Sphingosine kinase-1 activity and expression in human prostate cancer resection specimens. Eur J Cancer. 2010; 46:3417-3424.
32. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissie J, Malavaud B, Waxman J and Cuvillier O. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010; 70:8651-8661.
33. Pchejetski D, Bohler T, Stebbing J and Waxman J. Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol. 2011; 8:569-678.
34. Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissie J, Kohama T, Waxman J, Malavaud B and Cuvillier O. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther. 2008; 7:1836-1845.
35. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissie J, Malavaud B and Cuvillier O. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 2005; 65:11667-11675.
36. Pchejetski D, Nunes J, Coughlan K, Lall H, Pitson SM, Waxman J and Sumbayev VV. The involvement of sphingosine kinase 1 in LPS-induced Toll-like receptor 4-mediated accumulation of HIF-1alpha protein, activation of ASK1 and production of the pro-inflammatory cytokine IL-6. Immunol Cell Biol. 2011; 89:268-274.
37. Sauer L, Nunes J, Salunkhe V, Skalska L, Kohama T, Cuvillier O, Waxman J and Pchejetski D. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. Int J Cancer. 2009; 125:2728-2736.
38. Kershaw EE and Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89:2548-2556.
39. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L and Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372:425-432.
40. Li MD. Leptin and beyond: an odyssey to the central control of body weight. Yale J Biol Med. 2011; 84:1-7.
41. Sinha MK, Opentanova I, Ohannesian JP, Kolaczynski JW, Heiman ML, Hale J, Becker GW, Bowsher RR, Stephens TW and Caro JF. Evidence of free and bound leptin in human circulation. Studies in lean and obese subjects and during short-term fasting. The Journal of Clinical Investigation. 1996; 98:1277-1282.
42. Lam QL and Lu L. Role of leptin in immunity. Cell Mol Immunol. 2007; 4:1-13.
43. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, et al. Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995; 83:1263-1271.
44. Myers MG, Jr. Leptin receptor signaling and the regulation of mammalian physiology. Recent progress in hormone research. 2004; 59:287-304.
45. Mancour Liliya V, Daghestani Hikmat N, Dutta S, Westfield Gerwin H, Schilling J, Oleskie Austin N, Herbstman Jeffrey F, Chou Steven Z and Skiniotis G. Ligand-Induced Architecture of the Leptin Receptor Signaling Complex. Molecular Cell. 2012; 48:655-661.
46. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI and Morgenstern JP. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell. 1996; 84:491-495.
47. Banks AS, Davis SM, Bates SH and Myers MG. Activation of downstream signals by the long form of the leptin receptor. Journal of Biological Chemistry. 2000; 275:14563-14572.
48. Lothgren A, McCartney M, Rupp Thuresson E and James SR. A model of activation of the protein tyrosine phosphatase SHP-2 by the human leptin receptor. Biochim Biophys Acta. 2001; 9:1-2.
49. Bjorbaek C, Uotani S, da Silva B and Flier JS. Divergent signaling capacities of the long and short isoforms of the leptin receptor. J Biol Chem. 1997; 272:32686-32695.
50. Jiang L, Li Z and Rui L. Leptin stimulates both JAK2-dependent and JAK2-independent signaling pathways. The Journal of biological chemistry. 2008; 283:28066-28073.
51. Bjorbak C, Lavery HJ, Bates SH, Olson RK, Davis SM, Flier JS and Myers MG, Jr. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem. 2000; 275:40649-40657.
52. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, Haj F, Wang Y, Minokoshi Y, Kim Y-B, Elmquist JK, Tartaglia LA, Kahn BB and Neel BG. PTP1B Regulates Leptin Signal Transduction In Vivo. Developmental Cell. 2002; 2:489-495.
53. Noda T, Kikugawa T, Tanji N, Miura N, Asai S, Higashiyama S and Yokoyama M. Longterm exposure to leptin enhances the growth of prostate cancer cells. Int J Oncol. 2015; 46:1535-1542.
54. Hoda MR, Theil G, Mohammed N, Fischer K and Fornara P. The adipocyte-derived hormone leptin has proliferative actions on androgen-resistant prostate cancer cells linking obesity to advanced stages of prostate cancer. J Oncol. 2012; 280386:28.
55. Frankenberry KA, Somasundar P, McFadden DW and Vona-Davis LC. Leptin induces cell migration and the expression of growth factors in human prostate cancer cells. Am J Surg. 2004; 188:560-565.
56. Deo DD, Rao AP, Bose SS, Ouhtit A, Baliga SB, Rao SA, Trock BJ, Thouta R, Raj MH and Rao PN. Differential effects of leptin on the invasive potential of androgendependent and-independent prostate carcinoma cells. J Biomed Biotechnol. 2008; 2008:163902.
57. Habib CN, Al-Abd AM, Tolba MF, Khalifa AE, Khedr A, Mosli HA and Abdel-Naim AB. Leptin influences estrogen metabolism and accelerates prostate cell proliferation. Life Sci. 2015; 121:10-15.
58. Huang CY, Yu HS, Lai TY, Yeh YL, Su CC, Hsu HH, Tsai FJ, Tsai CH, Wu HC and Tang CH. Leptin increases motility and integrin up-regulation in human prostate cancer cells. J Cell Physiol. 2011; 226:1274-1282.
59. Ribeiro AM, Andrade S, Pinho F, Monteiro JD, Costa M, Lopes C, Aguas AP and Monteiro MP. Prostate cancer cell proliferation and angiogenesis in different obese mice models. Int J Exp Pathol. 2010; 91:374-386.
60. Surmacz E and Otvos L. Molecular targeting of obesity pathways in cancer. Horm Mol Biol Clin Investig. 2015; 22:53-62.
61. Catalano S, Leggio A, Barone I, De Marco R, Gelsomino L, Campana A, Malivindi R, Panza S, Giordano C, Liguori A, Bonofiglio D, Liguori A and Ando S. A novel leptin antagonist peptide inhibits breast cancer growth in vitro and in vivo. J Cell Mol Med. 2015; 19:1122-1132.
62. McMurphy T, Xiao R, Magee D, Slater A, Zabeau L, Tavernier J and Cao L. The anti-tumor activity of a neutralizing nanobody targeting leptin receptor in a mouse model of melanoma. PLoS One. 2014; 9:e89895.
63. Palmer J, Hertzog PJ and Hammacher A. Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells. Int J Biochem Cell Biol. 2004; 36:2258-2269.
64. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R and de Miguel MP. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol. 2004; 202:41-49.